

Oncogenic drivers in advanced NSCLC:

Navigating an evolving landscape
to optimize patient outcomes

ON DEMAND

14 – 29 September 2020

SPONSORED BY TAKEDA



Fiona Blackhall The University of Manchester, UK
Welcome and introduction

10
MINS



Fabrice Barlesi Institut Gustave Roussy, Paris, France
Oncogenic driver testing strategies:
Identifying the right patients for the right treatment

20
MINS



Max Hochmair Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Vienna, Austria
Treatment selection in ALK-positive metastatic NSCLC:
Optimizing outcomes

20
MINS



Rosario García Campelo University Hospital A Coruña, Spain
Reaching the sanctuary site: Options for patients
with ALK-positive NSCLC with brain metastases

20
MINS

Live interactive Q&A session: 22 September 15.30-16.00 CET

This symposium is sponsored by Takeda Oncology.

Takeda Oncology is a registered trademark of Takeda Pharmaceutical Company Limited.

© 2019 Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.

All Rights Reserved. 06/19 OMS/ONC/19/0010 (1)

Date of preparation: July 2020

Job number: VV-MEDMAT-22389



ONCOLOGY